count: 173 words 17 Text count: 6275 words 18 19 20 #Address correspondence to Stacy M. Horner, stacy.horner@duke.edu 21 49 such as such influenza A virus, this innate immune signaling pathway may also be 50 important in controlling other RNA virus infections. 51 52 53 and mitochondria and mitochondrial-ER contact sites (often referred to as mitochondrial-77 associated ER membranes (MAM)) for immune evasion (10-14). 78 Antiviral innate immune signaling against HCV can be initiated by the RNA sensor 79 proteins RIG-I and MDA5 (15-17). RIG-I is directly activated by multiple ubiquitination 80 events by E3 ubiquitin ligases, namely TRIM25 and Riplet, which binds to and adds K63-81 linked ubiquitin chains to RIG-I, but not MDA5 (18-21). Once activated, RIG-I and MDA5 82 signal to the adaptor protein MAVS to drive a signal transduction cascade that induces 83 the phosphorylation of IRF3 and then the transcriptional induction of interferon (IFN)-β. 84 HCV infected can also be sensed by TLR3, which signals via TRIF and IRF3 to induce 85 antiviral innate immunity (22). During HCV infection, NS3-NS4A cleaves and/or 86 inactivates MAVS (10, 12, 23, 24), TRIF (25) and Riplet (19) to block IRF3 activation (26). 87 Here, we aimed to uncouple the roles of NS3-NS4A in replication and immune 88 evasion. We focused on the NS4A transmembrane domain and found a residue, Y16, 89 that regulates differential inactivation of MAVS and Riplet, revealing a new branch of 90 innate immune signaling that controls HCV infection. 91 92
Abstract 22 The hepatitis C virus (HCV) NS3-NS4A protease complex is required for viral 23 replication and is the major viral innate immune evasion factor. NS3-NS4A evades 24 antiviral innate immunity by inactivating several proteins, including MAVS, the signaling 25 adaptor for RIG-I and MDA5, and Riplet, an E3 ubiquitin ligase that activates RIG-I. Here, 26 we identified a Tyr-16-Phe (Y16F) change in the NS4A transmembrane domain that 27 prevents NS3-NS4A targeting of Riplet but not MAVS. This Y16F substitution reduces 28 HCV replication in Huh7 cells, but not in Huh-7.5 cells, known to lack RIG-I signaling. 29 Surprisingly, deletion of RIG-I in Huh7 cells did not restore Y16F viral replication. Rather, 30 we found that Huh-7.5 cells lack Riplet expression and that addition of Riplet to these 31 cells reduced HCV Y16F replication. In addition, IRF3 deletion in Huh7 cells was sufficient 32 to restore HCV Y16F replication, and the Y16F protease lacked the ability to prevent IRF3 33 activation or interferon induction. Taken together, these data reveal that the NS4A Y16 34 residue regulates a non-canonical Riplet-IRF3-dependent, but RIG-I-MAVS-independent, 35 signaling pathway that limits HCV infection. 36 37 38 Importance 39 The HCV NS3-NS4A protease complex facilitates viral replication by cleaving and 40 inactivating the antiviral innate immune signaling proteins MAVS and Riplet, which are 41 essential for RIG-I activation. NS3-NS4A therefore prevents IRF3 activation and 42 interferon induction during HCV infection. Here, we uncover an amino acid residue within 43 the NS4A transmembrane domain that is essential for inactivation of Riplet, but does not 44 affect MAVS cleavage by NS3-NS4A. Our study reveals that Riplet is involved in a RIG-45 I-and MAVS-independent signaling pathway that activates IRF3 and that this pathway is 46 normally inactivated by NS3-NS4A during HCV infection. Our study selectively uncouples 47 these distinct regulatory mechanisms within NS3-NS4A and defines a new role for Riplet 48 in the antiviral response to HCV. As Riplet is known to be inhibited by other RNA viruses, Introduction 54 Hepatitis C virus (HCV) is a positive-sense, singled-stranded RNA virus that infects 55 over 70 million people worldwide, with up to 80% of infected individuals developing 56 chronic infection (1). The recent development of direct-acting antivirals for HCV has 57 dramatically improved successful treatment of HCV infection (2). However, many HCV-58 infected individuals are asymptomatic and thus unaware of their HCV status until 59 secondary manifestations, such as liver cirrhosis and hepatocellular carcinoma, arise 60 decades later. Notably, although the current direct-acting antivirals treat HCV-induced 61 disease, they do not always prevent re-infection in cured individuals. Therefore, there is 62 an urgent need for future studies into the development of a vaccine to reduce the global 63 burden of HCV infection (3). 64 Several factors contribute to the ability of HCV to establish a chronic infection, 65 including its ability to evade detection and dysregulate the host antiviral innate immune 66 response through the actions of the HCV NS3-NS4A protease complex (4). The NS3-67 NS4A protease is a protein complex formed between NS3, which contains protease and 68 helicase domains, and NS4A. NS4A is a 54 amino acid protein that contains an N-terminal 69 transmembrane domain, an NS3 interacting domain, and a C-terminal acidic domain (5). 70 The NS4A transmembrane domain anchors NS3 to membranes (6) and mediates NS4A 71 dimerization (7). NS3-NS4A has diverse functions in the HCV life cycle, with roles in HCV 72 RNA replication, viral assembly, and innate immune evasion (reviewed in (8))(9). The 73 mechanisms that regulate these diverse functions of NS3-NS4A are not completely 74 understood. However, it is known that NS4A directs the protease complex to distinct 75 intracellular membranes to perform some of these functions: the ER for viral replication; 76 transmembrane domain at the lipid bilayer interface (5, 7). Interestingly, aromatic residues 100 at the termini of transmembrane domains are often important for positioning membrane 101 proteins within lipid bilayers (43) (44) (45) . Therefore, we hypothesized that these residues may 102 play a role in the proper localization and/or function of the NS3-NS4A protease complex 103 during HCV infection. While both the W3 and the Y16 residues in NS4A are conserved 104 across the eight known HCV genotypes, we chose to focus specifically on the Y16 residue 105 (Fig. 1A) , with the goal of uncoupling the function of Y16 in HCV replication from targeting 106 of innate immune substrates, such as MAVS and Riplet. As a prior study found that a 107 Y16A substitution inhibited HCV replication (7), we made the more conservative 108 phenylalanine mutation (Y16F) to maintain aromaticity at this position. Here, we analyzed 109 the role of this amino acid in regulating HCV replication and innate immune regulation by 110 NS3-NS4A. 111 To determine if the Y16F substitution in NS4A altered HCV replication, we first 112 engineered this amino acid change into an HCV replicon encoding a G418 marker (HCV 113 genotype 1B subgenomic replicon; HP replicon (15)). Following in vitro transcription, wild-114 type (WT) or Y16F HCV replicon RNA was electroporated into either liver hepatoma Huh-115 7.5 cells, which do not have functional RIG-I signaling due to the T55I mutation (15), or 116 Huh7 cells, which have functional RIG-I signaling. In the Huh-7.5 cells, the number of 117 G418-resistant colonies in the WT versus the Y16F HCV replicon-transduced cells was 118 equivalent, indicating that WT and Y16F replicated similarly. However, in Huh7 cells, the 119 Y16F HCV replicon had a reduced transduction efficiency (~3-fold) compared to the WT 120 HCV replicon (Fig. 1B) . As control, we also measured the interaction of NS4A WT or 121 Y16F with NS3 by co-immunoprecipitation and found that the Y16F substitution did not 122 alter the interaction of NS4A with NS3, nor the ability of the NS3-NS4A protease to 123 process the NS3-NS4A polyprotein junction (Fig. 1C) . Together, these data reveal that 124 the Y16F mutation results in reduced HCV replication in Huh7 cells, but not Huh-7.5 cells, 125 suggesting that NS4A Y16F may regulate RIG-I-mediated innate immune signaling to 126 promote HCV immune evasion and replication. 127 128 RIG-I deletion in Huh7 cells does not restore HCV NS4A Y16F viral replication. 129 To determine if the Y16F substitution in NS4A specifically altered HCV replication 130 in Huh7 cells during infection, we engineered the NS4A Y16F substitution into the full-131 length HCV infectious clone (JFH1, genotype 2A (33)). We generated low-passage viral 132 stocks and confirmed that the Y16F mutation was maintained in the resulting virus by 133 PCR amplification of the NS4A region and Sanger sequencing. We then infected Huh-7.5 134 or Huh7 cells with the HCV WT or Y16F virus, harvested protein lysates over a time 135 course of infection, and measured HCV NS5A protein expression by immunoblot. We 136 found that HCV NS5A protein levels were equivalent in Huh-7.5 cells infected with WT or 137 Y16F HCV ( Fig. 2A ). However, in Huh7 cells, the level of NS5A protein from the Y16F 138 virus was reduced as compared to WT HCV (Fig. 2B ). In addition to RIG-I, there are likely 139 other genetic differences between Huh7 and Huh-7.5 cells. Thus, to determine if RIG-I 140 was the factor accounting for the differential replication observed between WT and Y16F 141 HCV in Huh7 cells versus Huh-7.5 cells, we generated Huh7-RIG-I knockout (KO) cells 142 using CRISPR/Cas9 genome editing. These Huh7-RIG-I KO cells contain a 252 143 nucleotide deletion that removes the start codon, preventing RIG-I protein expression 144 (Fig. 2C) . To confirm a loss of RIG-I signaling, we infected Huh7-RIG-I KO cells with 145 Sendai virus (SV), a virus known to activate RIG-I signaling (15, 46) , and observed no SV-146 mediated induction of RIG-I protein or signaling to the IFN-β promoter, which was restored 147 upon over-expression of RIG-I (15, 16) ( Fig. 2D) . 148 We next infected these Huh7-RIG-I KO cells with either WT or Y16F HCV and 149 measured HCV NS5A expression from lysates harvested over a time course of infection 150 by immunoblotting. Surprisingly, we found that NS5A protein level from Y16F HCV was 151 not restored to the level of WT in the Huh7-RIG-I KO cells ( Fig. 2E) . We then compared 152 the production of infectious virus from the WT and Y16F viruses in each of these cell lines. 153 In these assays, the supernatants of infected cells were used to infect naïve Huh-7.5 cells 154 to determine the viral titer, which ultimately measures a second round of infection. We 155 found that the while the Y16F virus harvested from Huh-7.5 cells resulted in a somewhat 156 lower level of infectious virus as compared to WT (~40% lower), its level of infectious virus 157 harvested from Huh7 or Huh7-RIG-I KO cells was significantly lower as compared to WT 158 (now ~75% lower) (Figs. 2F-2H). Taken together, these data suggest that NS4A Y16 159 regulates a RIG-I-independent signaling pathway that is non-functional in Huh-7.5 cells. 160 161 HCV NS3-NS4A Y16F retains the ability to cleave MAVS. 162 As NS4A Y16 is located at the membrane lipid bilayer interface (5, 7), and NS4A 163 membrane interactions regulate the molecular mechanisms by which the NS3-NS4A 164 protease targets substrates (7), we hypothesized that the Y16F substitution in NS4A may 165 regulate NS3-NS4A cleavage of MAVS. To test this, we co-expressed NS3-NS4A with 166 Flag-tagged MAVS and found that both NS3-NS4A WT and Y16F cleaved MAVS, while 167 NS3-NS4A containing a mutation that inactivates the protease active site (S139A; SA) 168 did not (Fig. 3A) . We also found that MAVS cleavage was similar following HCV WT and 169 Y16F infection in both Huh-7.5 and Huh7 cells (Fig. 3B) . Together, this reveals that the 170 NS4A Y16F substitution does not alter MAVS cleavage by NS3-NS4A. 171 172 IRF3 deletion in Huh7 cells restores HCV Y16F replication to the levels of HCV WT. 173 We next wanted to determine if the signaling pathway that inhibits HCV Y16F 174 replication requires the IFN-β transcription factor IRF3 (reviewed in (47)). We first 175 generated Huh7-IRF3 KO cells using CRISPR/Cas9 genome editing and determined 176 IRF3 expression and function in these cells by sequencing the IRF3 genetic locus, HCV NS3-NS4A Y16F does not block IRF3 activation. 189 As our data suggested that HCV Y16F replication was inhibited by IRF3-mediated 190 signaling, we hypothesized that NS3-NS4A Y16F would be unable to block IRF3 191 activation. During viral infection, IRF3 is activated by a multi-step process, including 192 phosphorylation by the kinases TBK1 and IKKε, resulting in dimerization, and finally 193 translocation from the cytosol to the nucleus, where it activates transcription of IFN-β (41). 194 Importantly, it is well-known that over-expression of the WT NS3-NS4A protease can 195 block this nuclear translocation of IRF3 in response to virus infection (12, 48). Therefore, 196 we measured the ability of WT or Y16F NS3-NS4A to block the nuclear translocation of HCV NS4A Y16F does not target Riplet. 218 Our data described thus far reveal that NS4A Y16 regulates NS3-NS4A inhibition 219 of IRF3-mediated antiviral signaling. This IRF3-mediated signaling, which limits HCV 220 replication, is RIG-I-independent and MAVS-cleavage independent. Together, these data 221 suggest: (1) that there is a factor that induces signaling to IRF3 that is targeted by NS4A 222 Y16 (and not Y16F), and (2) that this factor is present in Huh7 cells but absent or non-223 functional in Huh-7.5 cells. NS3-NS4A cleaves and inactivates three known host proteins 224 involved in the IRF3 signaling axis: MAVS, TRIF (the TLR3 signaling adaptor), and Riplet 225 (10, 12, 19, 24, 25, 48). Since we have demonstrated that NS3-NS4A Y16F cleaves 226 MAVS (Fig. 3) , and it is known that Huh7 cells do not have functional TLR3 signaling (49), 227 we hypothesized that the E3 ubiquitin ligase Riplet may be differentially regulated by NS3-228 NS4A WT and Y16F. Interestingly, we found that Huh-7.5 cells express reduced levels of 229 Riplet (RNF135) mRNA as compared to Huh7 cells (Fig. 6A) . This low level of Riplet likely 230 renders it incapable of driving signaling. Therefore, we tested if Riplet ectopic expression 231 in Huh-7.5 cells could limit HCV Y16F replication relative to HCV WT. We generated Huh-232 7.5 cells expressing V5-tagged Riplet (Figs. 6A-6B), infected these cells with HCV WT 233 or Y16F, and measured HCV NS5A expression. In Huh-7.5 + Riplet-V5 cells, but not Huh-234 7.5 cells, HCV Y16F replication was reduced compared to WT (Fig. 6B) . Similarly, the 235 amount of infectious virus generated in the Huh-7.5 + Riplet-V5 cells or Huh7 cells from 236 the HCV Y16F virus was also much lower than WT (~90% lower in each), but in the Huh-237 7.5 cells, the level of Y16F virus was still only partially reduced compared to WT, similar 238 to before (~50% lower) ( Fig. 6C, Fig. 2 ). We note that the overall levels of HCV replication 239 (both WT and Y16F) in the Huh-7.5 + Riplet-V5 cells were lower than those seen in the 240 parental Huh-7.5 cells, likely due to the higher levels of Riplet expression in these cells 241 ( Fig. 6 ) and the known role of Riplet in inhibiting HCV replication (19) . 242 To test the role of NS4A Y16 in targeting Riplet, we first examined the localization 243 of over-expressed NS3-NS4A WT or Y16F with HA-tagged Riplet in Huh7 cells by 244 immunofluorescence. Similar to others, we did not detect any major difference in the 245 localization of NS4A WT or Y16F (5). In cells expressing NS3-NS4A WT, we found that 246 Riplet was localized in small, punctate aggregates throughout the cytoplasm, whereas in 247 cells expressing NS3-NS4A Y16F, Riplet was diffusely localized throughout the 248 cytoplasm, similar to that seen in vector-expressing cells and described previously (18) 249 ( Fig. 7A) . We also found that in cells expressing NS3-NS4A WT, but not Y16F, Riplet 250 and NS4A were in close proximity to each other (Fig. 7A, zoom) , suggesting that NS4A 251 may interact with Riplet in a Y16-dependent manner. Indeed, we found that NS4A alone 252 interacted with Flag-tagged Riplet and that the Y16F mutation reduced this interaction by 253 approximately 70% (Fig. 7B ). Taken together, these data suggest that the NS4A Y16 254 residue is necessary for the ability of NS3-NS4A to interact with Riplet and to block NS4A. We found that mutation of NS4A Tyr-16 to phenylalanine, in both the context of an 260 HCV subgenomic RNA replicon and in the context of fully infectious HCV, results in 261 reduced viral replication in Huh7 cells, but not in Huh-7.5 cells. We show that both NS3-262 NS4A WT and Y16F cleave MAVS. Further, we found that Huh-7.5 cells, in addition to 263 lacking RIG-I signaling (15), express low levels of Riplet (Fig. 6) . Importantly, ectopic 264 expression of Riplet in Huh-7.5 cells resulted in reduced replication of HCV Y16F 265 compared to WT virus. We also found that NS4A WT binds to Riplet, while NS4A Y16F 266 does not bind as well. Taken together, this supports the model that HCV inactivates Riplet 267 to prevent signaling to IRF3 and an antiviral response that can inhibit HCV replication. 268 Our work reveals that the NS3-NS4A Y16 residue plays a critical role in the inactivation 269 of this signaling pathway. Thus, NS4A Y16 regulates an antiviral signaling program 270 activated by a Riplet-IRF3-dependent, but RIG-I-MAVS-independent, signaling axis. 271 We found that HCV containing an NS4A Y16F substitution in two HCV genotypes, 272 either the JFH1 genotype 2A virus or the HP genotype 1B subgenomic replicon, has lower 273 levels of replication than WT in Huh7 cells (Fig. 1B, Fig. 2A and 2B ), but that both the 274 WT and Y16F viruses have similar levels of replication in Huh-7.5 cells or in Huh7-IRF3 275 KO cells (Fig. 2B, Figs. 4C-4D ). Although we did find that in experiments that assessed 276 viral titer, the Y16F virus from Huh-7.5 cells had a reduced viral titer as compared to the 277 WT. However, this reduction (~50%) was not as much as that of virus harvested from the attempts to use CRISPR to delete Riplet from Huh7 cells were unsuccessful. 294 Nevertheless, as we found that the Y16F substitution does not affect either the interaction 295 of NS4A with NS3, processing of the NS3/NS4A junction, or MAVS cleavage, our results 296 suggest that it has a specific role in targeting NS3-NS4A to Riplet. 297 The mechanisms by which the HCV protease targets and inactivates Riplet are not 298 entirely clear. Riplet is an E3 ubiquitin ligase localized in the cytoplasm that activates RIG-299 I by both binding and adding K63-linked ubiquitin chains to it (20, 50). While others have 300 concluded that NS3-NS4A cleaves Riplet in the first amino acid of its RING domain 301 resulting in its destabilization (19), we were not able to detect a Riplet cleavage product 302 or a reduction in Riplet protein abundance by immunoblot analysis upon over-expression 303 of NS3-NS4A in cells, although we cannot rule out this possibility. While it is possible that 304 NS3-NS4A inactivation of Riplet via cleavage may result in its destabilization, analogous 305 to how NS3-NS4A cleavage of TRIF accelerates its proteolysis (25), it is also possible 306 that simply the binding of NS3-NS4A to Riplet can inactivate it. Indeed, we did find that 307 the localization of Riplet changed from cytoplasmic to punctate, often near NS4A, 308 following over-expression of NS3-NS4A WT, but not Y16F, which could either represent 309 a differential localization as a result of binding to NS4A to prevent Riplet function or 310 represent cleavage by the WT NS3-NS4A (Fig. 7A) . Indeed, the dengue virus protease 311 co-factor NS2 (analogous to HCV NS4A) inactivates cGAS simply by binding to it and 312 inducing its autophagic degradation (51). Additionally, the influenza A virus NS1 protein 313 inactivates Riplet by binding to it (37). Therefore, while it is clear that NS3-NS4A 314 inactivates Riplet, further studies are needed to determine the exact mechanisms by 315 which this occurs. 316 While HCV NS4A anchors the NS3-NS4A protease to intracellular membranes (6), 317 the mechanisms by which the Y16F substitution in NS4A would specifically alter Riplet 318 localization and block Riplet signaling are unclear. Similar to others, we did not find that 319 the Y16F substitution altered the localization of NS4A within membranes (5). Since NS4A 320 can bind Riplet in the absence of NS3, it is possible that NS4A Y16 is simply required for 321 Riplet binding, either directly or through other proteins. In fact, as the hydroxyl group of 322 this tyrosine residue in NS4A is positioned such that it interacts with the phospholipid 323 head groups of the membrane bilayer, while a phenylalanine at the position would be 324 missing this hydroxyl group, Y16 may be poised to mediate protein-protein interaction 325 directly with Riplet or with accessory binding proteins (5). We also note that it is possible 326 that phosphorylation of NS4A Y16 could regulate these protein-protein interactions. Thus, 327 NS4A Y16 likely mediates interactions with Riplet to prevent Riplet from interacting with 328 proteins that mediate antiviral innate immune signaling. 329 Our results suggest that HCV activates a Riplet-dependent signaling cascade to 330 IRF3 that is independent of both RIG-I and MAVS. The following pieces of evidence 331 presented within this manuscript support the existence of this pathway: (1) NS3-NS4A 332 WT and Y16F both cleave MAVS (Fig. 3) , (2) Y16F cannot bind to Riplet as well as WT 333 (Fig. 7); (3) NS3-NS4A WT, but not Y16F, blocks SV-mediated IRF3 activation and 334 induction of ISGs (Fig. 5) ; (4) WT and Y16F viruses only grow equivalently to each other 335 in cells that lack both RIG-I and Riplet or lack IRF3 (Fig. 1-2; Fig. 4) cells, ISGs are induced during HCV infection to limit Y16F viral replication. Indeed, we do 343 see a low level of IRF3 nuclear translocation in response to SV in these cells (Fig. 5D ). 344 Overall, this induction of this Riplet-IRF3 signaling pathway in the absence of RIG-I is 345 likely stimulus-dependent and cell type-dependent. 346 We do not yet know the full identity of this Riplet-IRF3 signaling cascade regulated 347 by NS3-NS4A Y16. We predict that Riplet is either directly adding K63-linked ubiquitin 348 chains to signaling proteins in this pathway or that it interacts with these signaling proteins Table 1 ). The resulting amplicons were cloned into pCR4- 
